Summit Therapeutics, Inc.
About Summit
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Ivonescimab is being developed in NSCLC, with three active Phase III trials:
HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).
HARMONi-3 is a Phase III clinical trial designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
HARMONi-7 is a Phase III clinical trial intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US FDA for the HARMONi clinical trial setting.
Overview Of Role The Senior Vice President (SVP), US Marketing will lead the development and execution of the U.S. marketing strategy for the company’s commercial asset, ivonescimab. As the top U.S. commercial leader for this brand, the SVP will be accountable for all aspects of U.S. marketing, including launch preparation, brand positioning, promotional strategy, digital/omnichannel marketing, HCP and patient engagement, and performance optimization. This is a highly visible and mission-critical role, with a mandate to build a best-in-class brand presence in the U.S. market, shape the organization’s commercial culture, and deliver strong business results.
Role And Responsibilities
Develop and lead the comprehensive U.S. marketing strategy for ivonescimab ensuring differentiation, strong market uptake, and sustained growth
Build the U.S. brand plan, including positioning, value proposition, messaging, and go-to-market strategy across channels and stakeholders
Own and drive U.S. launch readiness, including development of HCP and patient campaigns, sales force enablement, and market shaping activities.
Establish KPIs and performance metrics to guide execution and optimize impact pre- and post-launch
Builds and develops a high-performing, top-tier marketing team to execute strategic initiatives
Foster a culture of agility, accountability, innovation, and collaboration.
Collaborates cross-functionally to ensure alignment and seamless execution of strategic and tactical plans
Oversees investment planning and budget management to maximize brand growth and return on investment
Translates insights from market research, key opinion leader (KOL) engagement, and external stakeholders into actionable business opportunities
Aligns the organization around brand priorities and key growth opportunities, while proactively planning for potential competitive challenges
Owns and validates the brand’s revenue forecast, incorporating risk assessments and opportunity analyses
Drives innovation and adapts strategies to succeed in today’s dynamic launch and commercialization landscape
All other duties as assigned
Experience, Education And Specialized Knowledge And Skills
Advanced degree in Business, Marketing, Life Sciences, or a related field (MBA, MS, or PhD preferred)
Minimum of 15+ years of progressive experience in pharmaceutical marketing, with at least 7+ years in senior leadership roles
Demonstrated success in leading U.S. launch and/or commercialization of a specialty or first-in-class therapy
Must have recent launch experience; a large-scale brand with multiple competitors is a plus
Must have experience and understanding of U.S. market including key drivers and barriers; global experience is a plus
Proven track record of successfully commercializing Oncology pharmaceutical products, including immuno-oncology (I-O) experiences
Broad background across solid tumors is required; oncology lung experience is a plus
Sales experience, in addition to marketing, is a plus
Need to demonstrate understanding of innovative approaches to launches including digital marketing, SEO optimization, use of ML and AI for no see customers and just in time patients etc.
Keen grasp of the U.S. Oncology customer landscape, working with access and medical to ensure proper access and use of product
Understanding of compliance standards and acting within those standards
Demonstrated leadership, teamwork & team building and cross-functional collaboration
Must have drive, energy, persuasion, imagination, adaptability and versatility
Exceptional leadership, communication, and influencing skills
Analytical mindset with the ability to translate insights into impactful strategy
#J-18808-Ljbffr
Ivonescimab is being developed in NSCLC, with three active Phase III trials:
HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).
HARMONi-3 is a Phase III clinical trial designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
HARMONi-7 is a Phase III clinical trial intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US FDA for the HARMONi clinical trial setting.
Overview Of Role The Senior Vice President (SVP), US Marketing will lead the development and execution of the U.S. marketing strategy for the company’s commercial asset, ivonescimab. As the top U.S. commercial leader for this brand, the SVP will be accountable for all aspects of U.S. marketing, including launch preparation, brand positioning, promotional strategy, digital/omnichannel marketing, HCP and patient engagement, and performance optimization. This is a highly visible and mission-critical role, with a mandate to build a best-in-class brand presence in the U.S. market, shape the organization’s commercial culture, and deliver strong business results.
Role And Responsibilities
Develop and lead the comprehensive U.S. marketing strategy for ivonescimab ensuring differentiation, strong market uptake, and sustained growth
Build the U.S. brand plan, including positioning, value proposition, messaging, and go-to-market strategy across channels and stakeholders
Own and drive U.S. launch readiness, including development of HCP and patient campaigns, sales force enablement, and market shaping activities.
Establish KPIs and performance metrics to guide execution and optimize impact pre- and post-launch
Builds and develops a high-performing, top-tier marketing team to execute strategic initiatives
Foster a culture of agility, accountability, innovation, and collaboration.
Collaborates cross-functionally to ensure alignment and seamless execution of strategic and tactical plans
Oversees investment planning and budget management to maximize brand growth and return on investment
Translates insights from market research, key opinion leader (KOL) engagement, and external stakeholders into actionable business opportunities
Aligns the organization around brand priorities and key growth opportunities, while proactively planning for potential competitive challenges
Owns and validates the brand’s revenue forecast, incorporating risk assessments and opportunity analyses
Drives innovation and adapts strategies to succeed in today’s dynamic launch and commercialization landscape
All other duties as assigned
Experience, Education And Specialized Knowledge And Skills
Advanced degree in Business, Marketing, Life Sciences, or a related field (MBA, MS, or PhD preferred)
Minimum of 15+ years of progressive experience in pharmaceutical marketing, with at least 7+ years in senior leadership roles
Demonstrated success in leading U.S. launch and/or commercialization of a specialty or first-in-class therapy
Must have recent launch experience; a large-scale brand with multiple competitors is a plus
Must have experience and understanding of U.S. market including key drivers and barriers; global experience is a plus
Proven track record of successfully commercializing Oncology pharmaceutical products, including immuno-oncology (I-O) experiences
Broad background across solid tumors is required; oncology lung experience is a plus
Sales experience, in addition to marketing, is a plus
Need to demonstrate understanding of innovative approaches to launches including digital marketing, SEO optimization, use of ML and AI for no see customers and just in time patients etc.
Keen grasp of the U.S. Oncology customer landscape, working with access and medical to ensure proper access and use of product
Understanding of compliance standards and acting within those standards
Demonstrated leadership, teamwork & team building and cross-functional collaboration
Must have drive, energy, persuasion, imagination, adaptability and versatility
Exceptional leadership, communication, and influencing skills
Analytical mindset with the ability to translate insights into impactful strategy
#J-18808-Ljbffr